For its first fiscal quarter (ending March 31), Avanos Medical Inc (NYSE: AVNS) has reported E.P.S. of $0.01 compared to $-0.17 a year ago. This performance was $-0.37 short of the consensus estimate of $0.38. E.P.S. were $-0.03 for the latest four quarters through March 31 versus $0.38 for the same period a year ago — a decline of -108%.
Recent Price Action
Avanos Medical Inc (NYSE: AVNS) stock closed at $19.71 on 5/2/24 after a large increase of 4.9%. Moreover, trading volume in this advance was unusually high at 151% of normal. The stock has risen 5.3% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, AVNS is expected to be a modest Value Builder.
Avanos Medical has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Avanos Medical has a good Appreciation Score of 74 but a poor Power Rating of 22, with the Low Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment